Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.

Abstract

Twenty patients with advanced progressing Parkinson's disease have been treated with the 8-alpha-ergoline CU 32-085 in combination therapy for 3 months. With a mean daily dose of 12.65 mg, CU 32-085 together with levodopa plus a decarboxylase inhibitor produced a significant reduction in akinesia, rigor and tremor. Adverse reactions were rare and mild; in one case the drug was discontinued because of dyskinetic movements. Many of the pre-existing side effects were reduced or eliminated, particularly the involuntary movements and the levodopa response swings. The compound was considered useful in the treatment of advanced, progressing Parkinson's disease.

• Authors: H Biesemeyer, H P Ludin, E Ringwald
• Journal: Journal of neurology (J Neurol) Vol. 230 Issue 1 Pg. 19-23 ( 1983) ISSN: 0340-5354 [Print] Germany
• PMID: 6194269 (Publication Type: Journal Article)

Chemical References

• Antiparkinson Agents
• Ergolines
• Parasympatholytics
• Bromocriptine
• Levodopa
• Amantadine
• Carboxy-Lyases
• mesulergine

Topics

• Adult
• Aged
• Amantadine (administration & dosage)
• Antiparkinson Agents
• Bromocriptine (administration & dosage)
• Carboxy-Lyases (antagonists & inhibitors)
• Drug Therapy, Combination
• Ergolines (administration & dosage)
• Female
• Humans
• Levodopa (administration & dosage)
• Male
• Middle Aged
• Parasympatholytics (administration & dosage)
• Parkinson Disease (drug therapy)